Trial Profile

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sumatriptan (Primary)
Indications Migraine
Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

25 Apr 2012 Actual patient number changed from 479 to 514 as reported by ClinicalTrials.gov.
04 Oct 2011 Detailed results are expected to be presented at the 54th Annual Scientific Meeting of the American Headache Society (AHS), as reported in a NuPathe media release.
03 Oct 2011 Status changed from active, no longer recruiting to completed, according to a NuPathe media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com